Cargando…
Tumour biology, metastatic sites and taxanes sensitivity as determinants of eribulin mesylate efficacy in breast cancer: results from the ERIBEX retrospective, international, multicenter study
BACKGROUND: Our retrospective, international study aimed at evaluating the activity and safety of eribulin mesylate (EM) in pretreated metastatic breast cancer (MBC) in a routine clinical setting. METHODS: Patients treated with EM for a locally advanced or MBC between March 2011 and January 2014 wer...
Autores principales: | Dell’Ova, Mélodie, De Maio, Eléonora, Guiu, Séverine, Roca, Lise, Dalenc, Florence, Durigova, Anna, Pinguet, Frédéric, Bekhtari, Khedidja, Jacot, William, Pouderoux, Stéphane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599752/ https://www.ncbi.nlm.nih.gov/pubmed/26449988 http://dx.doi.org/10.1186/s12885-015-1673-3 |
Ejemplares similares
-
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019) -
Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012) -
Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
por: Noujaim, Jonathan, et al.
Publicado: (2016) -
Eribulin mesylate exerts antitumor effects via CD103
por: Oya, Kazumasa, et al.
Publicado: (2023) -
Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)